Analyst: Next sclerosis trigger awaits
Multiple sclerosis could be the next major medical adventure for Danish biotech company Genmab, but one important question has yet to be answered.
by Leonora Beck
Last week, Genmab announced some great news. The Danish biotech company, mostly known for its cancer drugs, and its partner GlaxoSmithKline (GSK) presented promising data for the drug ofatumumab in the treatment of relapsing-remitting multiple sclerosis (RRMS), the most common form of the debilitating disease.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler:
Genmab to expand Arzerra
For abonnenter
Genmab-CEO: Drug could be ready in 2016
For abonnenter
